EA200970517A1 - Соли 3-(3-амино-2-(r)-гидроксипропил)-1-(4-фторфенил)-8-(8-метилнафталин-1-илметил)-1,3,8-триазаспиро[4,5]декан-4-она - Google Patents

Соли 3-(3-амино-2-(r)-гидроксипропил)-1-(4-фторфенил)-8-(8-метилнафталин-1-илметил)-1,3,8-триазаспиро[4,5]декан-4-она

Info

Publication number
EA200970517A1
EA200970517A1 EA200970517A EA200970517A EA200970517A1 EA 200970517 A1 EA200970517 A1 EA 200970517A1 EA 200970517 A EA200970517 A EA 200970517A EA 200970517 A EA200970517 A EA 200970517A EA 200970517 A1 EA200970517 A1 EA 200970517A1
Authority
EA
Eurasian Patent Office
Prior art keywords
triazaspiro
decan
hydroxypropyl
amino
salts
Prior art date
Application number
EA200970517A
Other languages
English (en)
Inventor
Стивен Дж. Мехрман
Армин Ресслер
Роджер Фесслер
Фрэнк Дж. Виллани
Жан Франсуа Александр Люка Эжии
Original Assignee
Янссен Фармацевтика Н.В.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=39145092&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=EA200970517(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Янссен Фармацевтика Н.В. filed Critical Янссен Фармацевтика Н.В.
Publication of EA200970517A1 publication Critical patent/EA200970517A1/ru

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/10—Spiro-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/438—The ring being spiro-condensed with carbocyclic or heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/32—Alcohol-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/38—Drugs for disorders of the endocrine system of the suprarenal hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/06—Antiarrhythmics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Psychiatry (AREA)
  • Diabetes (AREA)
  • Pain & Pain Management (AREA)
  • Addiction (AREA)
  • Pulmonology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Endocrinology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Emergency Medicine (AREA)
  • Child & Adolescent Psychology (AREA)
  • Urology & Nephrology (AREA)
  • Hospice & Palliative Care (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)

Abstract

Настоящее изобретение относится к солям 3-(3-амино-2-(R)-гидроксипропил)-1-(4-фторфенил)-8-(8-метилнафталин-1-илметил)-1,3,8-триазаспиро[4,5]декан-4-она, фармацевтическим композициям, содержащим их, и их применению в лечении нарушений и состояний, модулированных НОР, например депрессия, беспокойство, злоупотребления алкоголем и т.д. Настоящее изобретение далее относится к способам получения 3-(3-амино-2-(R)-гидроксипропил)-1-(4-фторфенил)-8-(8-метилнафталин-1-илметил)-1,3,8-триазаспиро[4,5]декан-4-она и его соответствующих солей.
EA200970517A 2006-11-28 2007-11-14 Соли 3-(3-амино-2-(r)-гидроксипропил)-1-(4-фторфенил)-8-(8-метилнафталин-1-илметил)-1,3,8-триазаспиро[4,5]декан-4-она EA200970517A1 (ru)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US86137806P 2006-11-28 2006-11-28
PCT/US2007/084642 WO2008067167A1 (en) 2006-11-28 2007-11-14 Salts of 3-(3-amino-2-(r)-hydroxy-propyl)-1-(4-fluoro-phenyl)-8-(8-methyl-naphthalen-1-ylmethyl)-1,3,8-triaza-spiro[4.5]decan-4-one

Publications (1)

Publication Number Publication Date
EA200970517A1 true EA200970517A1 (ru) 2009-12-30

Family

ID=39145092

Family Applications (1)

Application Number Title Priority Date Filing Date
EA200970517A EA200970517A1 (ru) 2006-11-28 2007-11-14 Соли 3-(3-амино-2-(r)-гидроксипропил)-1-(4-фторфенил)-8-(8-метилнафталин-1-илметил)-1,3,8-триазаспиро[4,5]декан-4-она

Country Status (19)

Country Link
US (1) US8703948B2 (ru)
EP (1) EP2102206B1 (ru)
JP (1) JP5727139B2 (ru)
KR (1) KR20090083954A (ru)
CN (2) CN103202840B (ru)
AR (1) AR063982A1 (ru)
AU (1) AU2007325355A1 (ru)
CA (1) CA2670858C (ru)
CL (1) CL2007003406A1 (ru)
CR (1) CR10898A (ru)
EA (1) EA200970517A1 (ru)
EC (1) ECSP099365A (ru)
IL (1) IL198793A0 (ru)
MX (1) MX2009005641A (ru)
NO (1) NO20092416L (ru)
PE (1) PE20081300A1 (ru)
TW (1) TW200838862A (ru)
UY (1) UY30746A1 (ru)
WO (1) WO2008067167A1 (ru)

Family Cites Families (54)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3155699A (en) * 1960-03-30 1964-11-03 Mobay Chemical Corp Purification of isocyanates by reduction of the hydrolyzable chlorine and acid content
US3161644A (en) * 1962-06-22 1964-12-15 Res Lab Dr C Janssen N V 1-benzyl-4-substituted piperidines
US3155670A (en) * 1962-06-22 1964-11-03 Res Lab Dr C Janssen N V 1-oxo-2, 4, 8, triaza-spiro (4, 5) decanes
US3238216A (en) * 1963-06-20 1966-03-01 Res Lab Dr C Janssen N V Substituted 1, 3, 8-triaza-spiro (4, 5) decanes
US3839340A (en) * 1968-09-27 1974-10-01 Fmc Corp Substituted 1,3,8-triazaspiro{8 4.5{9 decanes
US3629267A (en) * 1968-10-28 1971-12-21 Smith Kline French Lab Benzoheterocyclicalkyl derivatives of 4-(2-keto -1-benzimidazolinyl)-piperidine 4-(2-keto - 1 - benzimidazolinyl) -1 2 3 6 tetrahydropyridine 1 - phenyl - 1 3 8-triazaspiro(4 5)decan - 4 - one and 2 4 9-triazaspiro(5 5)undecan-1 3 5-trione
US3859340A (en) * 1970-09-09 1975-01-07 Squibb & Sons Inc ' -methylfluorene-2-acetic acid
US4020072A (en) * 1976-05-04 1977-04-26 E. R. Squibb & Sons, Inc. 5-Aminomethyl-1H-pyrazolo[3,4-b]pyridines
JPS54109983A (en) * 1978-02-13 1979-08-29 Sumitomo Chem Co Ltd Novel spiroamine derivative and its preparation
US4329363A (en) * 1978-09-08 1982-05-11 Merck & Co., Inc. Substituted mercapto acid amides and their use
US4526896A (en) * 1978-12-26 1985-07-02 Riker Laboratories, Inc. Tetrazol-5-yl 2-nitro-3-phenylbenzofurans and antimicrobial use thereof
JPS57212180A (en) * 1981-06-19 1982-12-27 Yoshitomi Pharmaceut Ind Ltd Tetrahydrofuran(thiophene) compound
WO1988000190A1 (en) 1986-06-25 1988-01-14 Massachusetts Institute Of Technology Optically active derivatives of glycidol
US5486362A (en) * 1991-05-07 1996-01-23 Dynagen, Inc. Controlled, sustained release delivery system for treating drug dependency
DE4135473A1 (de) * 1991-10-28 1993-04-29 Bayer Ag Triazaspirodecanon-methylchromane
WO1993012789A1 (en) 1991-12-27 1993-07-08 Beth Israel Hospital Use of spiperone or spiperone derivatives as immunosuppressant agents
FR2708606B1 (fr) * 1993-07-30 1995-10-27 Sanofi Sa Dérivés du N-phénylalkylindol-2-one, leur préparation, les compositions pharmaceutiques en contenant.
ES2148347T3 (es) 1993-09-09 2000-10-16 Scios Inc Antagonistas del receptor de la bradiquinina pseudo y no peptidica.
US5739336A (en) * 1995-06-23 1998-04-14 Syntex (U.S.A.) Inc. 1,3,8-triaza- and 3,8-diaza-1-oxaspiro 4,5! decane derivatives
US5821219A (en) 1995-08-11 1998-10-13 Oregon Health Sciences University Opioid antagonists and methods of their use
ATE261942T1 (de) 1996-03-29 2004-04-15 Pfizer 6-phenylpyridinderivate
CA2226058C (en) 1997-01-30 2008-01-29 F. Hoffmann-La Roche Ag 8-substituted-1,3,8-triaza-spiro[4.5]decan-4-one derivatives
US6013652A (en) * 1997-12-04 2000-01-11 Merck & Co., Inc. Spiro-substituted azacycles as neurokinin antagonists
PT921125E (pt) * 1997-12-05 2002-06-28 Hoffmann La Roche Derivados de 1,38-triaza-espiro 4,5 decan-4-ona
SI0921125T1 (en) 1997-12-05 2002-04-30 F. Hoffmann-La Roche Ag 1,3,8-Triazaspiro(4,5)decan-4-on derivatives
EP1080091A1 (en) 1998-05-18 2001-03-07 Novo Nordisk A/S Novel 1,3,8-triazaspiro[4.5]decanones with high affinity for opioid receptor subtypes
US6277991B1 (en) * 1998-05-18 2001-08-21 Novo Nordisk A/S 1,3,8-triazaspiro[4.5]decanones with high affinity for opioid receptor subtypes
DE69900220T2 (de) * 1998-06-12 2002-05-08 Hoffmann La Roche Diaza-spiro[3,5]nonan-Derivate
EP1087770A4 (en) * 1998-06-15 2001-11-14 Merck & Co Inc INHIBITORS OF PRENYL PROTEIN TRANSFERASE
ID29137A (id) 1998-07-27 2001-08-02 Schering Corp Ligan-ligan afinitas tinggi untuk reseptor nosiseptin orl-1
US6262066B1 (en) * 1998-07-27 2001-07-17 Schering Corporation High affinity ligands for nociceptin receptor ORL-1
US6326379B1 (en) 1998-09-16 2001-12-04 Bristol-Myers Squibb Co. Fused pyridine inhibitors of cGMP phosphodiesterase
ES2237047T3 (es) * 1998-10-23 2005-07-16 Pfizer Inc. Compuestos de 1,3,8-triazaespiro(4,5)decanona como agonistas del receptor orl1.
IL143137A0 (en) 1998-11-20 2002-04-21 Smithkline Beecham Spa Quinoline-4-carboxamide derivatives as nk-3 and nk-2 receptor antagonists
JP2000169476A (ja) 1998-12-09 2000-06-20 Banyu Pharmaceut Co Ltd ４−オキソイミダゾリジン−５−スピロ−含窒素複素環式化合物
WO2001036418A1 (en) 1999-11-17 2001-05-25 Novo Nordisk A/S Novel triazaspirodecanones with high affinity for opioid receptor subtypes
DE19956598A1 (de) 1999-11-25 2001-06-13 Bosch Gmbh Robert Ventil zum Steuern von Flüssigkeiten
DE60033071T2 (de) 1999-12-06 2007-08-23 Euro-Celtique S.A. Triazospiroverbindungen mit nociceptin-rezeptoraffinität
JP2005231995A (ja) 1999-12-22 2005-09-02 Meiji Seika Kaisha Ltd オピオイドδ受容体アゴニスト／アンタゴニストとして有用なスピロ化合物
GB0003224D0 (en) * 2000-02-11 2000-04-05 Glaxo Group Ltd Chemical compounds
US6482829B2 (en) 2000-06-08 2002-11-19 Hoffmann-La Roche Inc. Substituted heterocyclic siprodecane compound active as an antagonist of neurokinin 1 receptor
WO2001096337A1 (fr) 2000-06-14 2001-12-20 Banyu Pharmaceutical Co.,Ltd Composes heterocycliques 4-oxoimidazolidine-2-spiro-azotes
NZ570181A (en) * 2001-04-10 2010-02-26 Ortho Mcneil Janssen Pharm 1,3,8-Triazaspiro[4.5]decan-4-one derivatives useful for the treatment of ORL-1 receptor mediated disorders
YU82403A (sh) 2001-04-18 2006-08-17 Euroceltique S.A. Jedinjenja spiropirazola
US20030078278A1 (en) * 2001-06-26 2003-04-24 Pfizer Inc. Spiropiperidine compounds as ligands for ORL-1 receptor
CA2454785C (en) 2001-07-23 2010-09-07 Banyu Pharmaceutical Co., Ltd. 4-oxoimidazolidine-2-spiropiperidine derivatives
US20040014955A1 (en) * 2001-12-17 2004-01-22 Carlos Zamudio Identification of essential genes of cryptococcus neoformans and methods of use
WO2003064425A1 (en) * 2002-01-28 2003-08-07 Pfizer Japan Inc. N-substituted spiropiperidine compounds as ligands for orl-1 receptor
EA009369B1 (ru) * 2002-09-09 2007-12-28 Янссен Фармацевтика, Н.В. Производные гидроксизамещенного 1,3,8-триазинспиро[4,5]декан-4-она, полезные для лечения расстройств, опосредованных orl-рецептором
WO2006023852A2 (en) * 2004-08-19 2006-03-02 Vertex Pharmaceuticals, Incorporated Modulators of muscarinic receptors
EP1890696A4 (en) * 2005-06-02 2010-05-05 Janssen Pharmaceutica Nv Suitable as new ORL-1 receptor modulators are 3-pyrolytic indolyl derivatives
EA200970518A1 (ru) * 2006-11-28 2009-12-30 Янссен Фармацевтика, Н.В. Способы лечения злоупотребления алкоголем, хронического алкоголизма и алкогольной зависимости
MX2009011006A (es) 2007-04-09 2009-11-02 Janssen Pharmaceutica Nv Derivados de 1,3,8-trisustituido-1,3,8-triaza-espiro[4.5]decano-4- ona como ligandos del receptor de orl-1 para el tratamiento de ansiedad y depresion.
US20100076003A1 (en) 2008-09-19 2010-03-25 Kathleen Battista 5-oxazolidin-2-one substituted 1,3,8-triazaspiro[4.5]decan-4-one derivatives useful as orl-1 receptor modulators

Also Published As

Publication number Publication date
WO2008067167A1 (en) 2008-06-05
ECSP099365A (es) 2009-06-30
AR063982A1 (es) 2009-03-04
PE20081300A1 (es) 2008-09-17
UY30746A1 (es) 2008-05-31
AU2007325355A1 (en) 2008-06-05
CN101622254B (zh) 2013-05-29
CN101622254A (zh) 2010-01-06
EP2102206A1 (en) 2009-09-23
NO20092416L (no) 2009-08-21
US20080176882A1 (en) 2008-07-24
IL198793A0 (en) 2010-02-17
MX2009005641A (es) 2009-06-05
CA2670858A1 (en) 2008-06-05
KR20090083954A (ko) 2009-08-04
JP5727139B2 (ja) 2015-06-03
CA2670858C (en) 2015-01-13
CL2007003406A1 (es) 2008-08-22
TW200838862A (en) 2008-10-01
CN103202840A (zh) 2013-07-17
CN103202840B (zh) 2015-02-11
CR10898A (es) 2009-10-30
US8703948B2 (en) 2014-04-22
JP2010511054A (ja) 2010-04-08
EP2102206B1 (en) 2015-04-08

Similar Documents

Publication Publication Date Title
EA201200951A1 (ru) Определенные триазолопиридины и триазолопиразины, их композиции и способы их применения
ATE410424T1 (de) Spirocyclische cyclohexan-derivate
EA200800514A1 (ru) Замещённые 7-азаиндазолы, содержащие их композиции, способ получения и применения
EA201300620A1 (ru) ПРОИЗВОДНЫЕ ИМИДАЗО[1,2-b]ПИРИДАЗИНА И ИМИДАЗО[4,5-b]ПИРИДИНА В КАЧЕСТВЕ ИНГИБИТОРОВ JAK
TN2012000265A1 (en) Triazolopyridines
EA201492112A1 (ru) ЗАМЕЩЕННЫЕ 3,4-ДИГИДРО-2H-ПИРИДО[1,2-a]ПИРАЗИН-1,6-ДИОНОВЫЕ ПРОИЗВОДНЫЕ, ПРИМЕНИМЫЕ ДЛЯ ЛЕЧЕНИЯ (В ТОМ ЧИСЛЕ) БОЛЕЗНИ АЛЬЦГЕЙМЕРА
WO2008115974A3 (en) Pyrazolopyrimidine analogs and their use as mtor kinase and pi3 kinase inhibitors
EA200702253A1 (ru) Фармацевтическая композиция
DE502005008971D1 (de) Substituierte 1,4,8-triazaspiroä4.5 decan-2-on-verbindungen zur behandlung von fettsucht
CO6220948A2 (es) Derivados de ciclohexano espirociclico
DE502005007459D1 (de) SUBSTITUIERTE 1,4,8-TRIAZASPIROi4.5 DECAN-2-ON-VERBINDUNGEN
WO2007136689A3 (en) Crystalline forms and processes for the preparation of phenyl-pyrazoles useful as modulators of the 5-ht2a serotonin receptor
EA200802407A1 (ru) Замещенные аминопиразолопиридины и их соли, их получения и фармацевтические композиции, которые их содержат
EA201070804A1 (ru) (аза)индольное производное, замещенное по положению 5, содержащая его фармацевтическая композиция, промежуточные соединения и способ их получения
EA201490630A1 (ru) 6-замещенные 3-(хинолин-6-илтио)[1,2,4]триазоло[4,3-a]пиридины в качестве ингибиторов c-met тирозинкиназы
MX2010009756A (es) Agonistas de receptores muscarinicos, composiciones, metodos de tratamiento de los mismos, y proceso para preparacion de los mismos.
EA200701688A1 (ru) Замещённые пирролы, содержащие их композиции, способ получения и применение
UA110245C2 (en) 7-(heleroaryl-amino)-6,7,8,9-letrahydropyrido[1,2-a]indol acetic acid derivatives and their application as prostaglandin d2 receptor modulators
WO2010033451A3 (en) 5-oxazolidin-2-one substituted 1,3,8-triazaspiro [4.5] decan-4-one derivatives useful as orl-1 receptor modulators
EA200970517A1 (ru) Соли 3-(3-амино-2-(r)-гидроксипропил)-1-(4-фторфенил)-8-(8-метилнафталин-1-илметил)-1,3,8-триазаспиро[4,5]декан-4-она
ITMI20052515A1 (it) Formulazione farmaceutica per il trattamento della osteoartrite
AU2013368997A8 (en) Solid form of dihydro-pyrido-oxazine derivative
BR112014009288A2 (pt) formas sólidas de 1,l-dioxo-4-tiomorfolinil)-[6-[[3(4-fluorofenil)-5-metil-4-isoxazolil]metóxi]-3-piridinil]-metanona
EA201170268A1 (ru) Соединения с серотонинергической активностью, способ их получения и содержащие их фармацевтические композиции
EA201591023A1 (ru) Твердая форма производного дигидропиридооксазина